Manufacture of vaccine clinical lot

Concepts

• manufacture of vaccine clinical lot
• york
• research and development
• testing of tox lot
• clinical lot of leishmaniasis vaccine covering
• manufacture of a clinical lot
• clinical material
• consultancy services
• testing of drug substance
• gmp production

Location

YORK

Description

Manufacture of a clinical lot of leishmaniasis vaccine

Total Quantity or Scope

Manufacture of a clinical lot of leishmaniasis vaccine covering; Compatability study: Production and Testing of Tox Lot, Clinical Material: GMP Production and Testing of Drug Substance (DS), Clinical Material: Production and Testing of Drug Product (DP), Clinical Material:

Award Detail

CPV Codes

• 73000000 - Research and development services and related consultancy services

Indicators

Legal Justification

The University of York (including its associated entities) intends to contract with the enclosed provider for the manufacture of a vaccine clinical lot for a 42 month period commencing 1st July 2022 without a call for competition. The University's reasons are: • The clinical lot is required to be compatible in manufacture with that previously used in clinical trials by the University of York, requiring manufacture using the cell line "Procell 92". The contractor were co-designers of the vaccine used in the clinical trials. • Only the contractor is authorised by the owners of Procell 92 (GSK) to use this cell line for manufacture of a Leishmaniasis vaccine